Contribution of Aging, Obesity, and Microbiota on Tumor Immunotherapy Efficacy and Toxicity

Area of Science:

• Immunology
• Oncology
• Microbiome Research

Background:

• Cancer immunotherapy offers significant promise but faces challenges like limited patient response rates and treatment-related toxicity.
• Biomarkers are crucial for predicting patient response and minimizing side effects.
• Host factors, including aging, obesity, and gut microbiome composition, significantly influence immune responses and immunotherapy outcomes.

Purpose of the Study:

• To review the current understanding of how aging, obesity, and the gut microbiome affect anti-tumor immunity and cancer immunotherapy.
• To explore the potential of these host factors in explaining discrepancies between preclinical models and clinical trial results.
• To propose future research directions for improving patient selection and treatment strategies in cancer immunotherapy.

Main Methods:

• Literature review of recent studies on host factors and cancer immunotherapy.
• Analysis of data linking aging, obesity, and gut microbiome to immune responses.
• Synthesis of findings to identify knowledge gaps and future research avenues.

Main Results:

• Aging, obesity, and gut microbiome composition demonstrably influence anti-tumor immune responses.
• These host factors may contribute to variability in immunotherapy efficacy observed in clinical settings.
• Differences in host factors between animal models and humans could explain translational challenges.

Conclusions:

• Host factors represent critical determinants of cancer immunotherapy success.
• Further research into aging, obesity, and the gut microbiome is essential for developing personalized immunotherapy approaches.
• Targeting or considering these host factors may enhance patient selection and treatment efficacy, ultimately improving patient outcomes.